RenovoCath Device Secures First Japanese Patent Allowance, Bolstering Global IP and Asia Expansion
RNXT sits 38% above its 52-week low of $0.701.
Summary
RenovoRx has secured its first Notice of Allowance for a Japanese patent covering its RenovoCath device, designed for targeted drug-delivery. This development significantly strengthens the company's global intellectual property portfolio, which now includes 19 issued or allowed patents, and supports its long-term commercial strategy in the strategically important Japanese market. The patent protects the RenovoCath's dual-occlusion catheter-based system, which enables localized drug infusion via the vasa vasorum, potentially improving outcomes and minimizing systemic toxicities. This positive news follows recent milestones, including surpassing 100 patients in its TIGeR-PaC clinical trial and reporting $1.1 million in RenovoCath revenue for 2025, indicating continued progress in both clinical development and commercialization. Traders will watch for future announcements regarding potential partnerships or commercialization efforts in Japan.
At the time of this announcement, RNXT was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.5M. The 52-week trading range was $0.70 to $1.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.